CURRICULUM VITAEAlan Kooi Davis, Ph.D.Date: November 2020DEMOGRAPHIC AND PERSONAL INFORMATIONAcademic Appointments2019 - Present Assistant ProfessorCollege of Social WorkThe Ohio State UniversityColumbus, OH2019 - Present Adjunct Assistant ProfessorCenter for Psychedelic and Consciousness ResearchDepartment of Psychiatry and Behavioral SciencesJohns Hopkins UniversityBaltimore, MDContact Information1947 College Rd. Columbus, OH 43210Email: [email protected] / [email protected]: Ohio State / Research Gate / Johns Hopkins / Source Research FoundationInterviews/Media and PresentationsRadio/Podcasts: JAMA / NPR / WPR / WBUR / Research Matters / Here We ArePrint/Online: CNN / Elemental / Newsweek / Vogue / Men’s Journal / Vox / Daily Mail /Hopkins Magazine / Big Think / NY Post / Vice / Psychology Today / Science DailyAudio/Video Presentations: Ohio State University / Yale / University of Michigan / Horizons-NYC/ Psilocybin SummitEducation and Training2008 – 2010Bachelor of Liberal Studies, Human Services - Summa Cum LaudeWingate University - Wingate, NC2010 – 2012Master of Arts, Clinical PsychologyBowling Green State University - Bowling Green, OH2012 – 2016Doctor of Philosophy, Clinical Psychology (APA Accredited)Bowling Green State University - Bowling Green, OH2015 – 2016Predoctoral Psychology Internship in Clinical Psychology (APA Accredited)VA Maryland Healthcare System& University of Maryland School of Medicine Consortium - Baltimore, MD2016 – 2017NIAAA T32 Postdoctoral Research FellowAddiction Center, Department of PsychiatryUniversity of Michigan - Ann Arbor, MI2017 – 2017Graduate Certificate in Psychedelic-assisted Therapy and ResearchCalifornia Institute of Integral Studies - San Francisco, CA2017 – 2019NIDA T32 Postdoctoral Research FellowBehavioral Pharmacology Research Unit, Department of PsychiatryJohns Hopkins University School of Medicine - Baltimore, MD

Professional Experience2005 – 2009Paraprofessional, Addiction Counselor, Director of Treatment ServicesMcLeod Addictive Disease Center - Charlotte, NC2017 – 2018Clinical Trial Assessment Rater for MDMA-assisted Therapy StudiesMultidisciplinary Association of Psychedelic StudiesMAPS Public Benefit Corporation – Santa Cruz, CARESEARCH ACTIVITIESResearch Focus1) Exploring the acute and persisting effects of psychoactive substances2) Understanding determinants of problematic patterns of substance use and associated harms3) Investigating the individual and systemic barriers to addiction treatment retention and successful outcomes4) Examining novel psychological and pharmacological interventions.Editorial Board Appointments2013 – 2015Editorial Advisory Board (Member)The Journal of NAADAC: Advances in Addiction & Recovery2019 – 2020Guest Editor (with Jason Luoma, Rosalind Watts, and Lance McCracken)Special Section on Psychedelic ScienceJournal of Contextual Behavioral Science2020 – Present Associate EditorJournal of Psychedelic StudiesAd-hoc reviewerAddiction; Human Psychopharmacology: Clinical and Experimental; Drug and Alcohol Dependence; Journal ofPsychopharmacology; Psychopharmacology; Journal of Contextual Behavioral Science; Drug Science, Policy, and Law;Addictive Behaviors; Psychology of Consciousness: Research, Theory, and Practice; Psychology of AddictiveBehaviors; PLOS One; Complimentary Therapies in Medicine; American Journal of Drug and Alcohol Abuse; Journalof Psychoactive Drugs; Addiction Research and Theory; Substance Abuse; Journal of Studies on Alcohol and Drugs;Journal of Psychedelic Studies; Journal of Alcohol and Alcoholism; Social Psychiatry and Psychiatric EpidemiologyPublications(GS metrics: h-index 13, i10 21, citations 540)underlined text indicates mentee statusBook Chapters1. Lancelotta, R. & Davis, A K. (2021). Therapeutic potential of fast-acting tryptamines. In C. Grob and J. Grigsby(Eds.), Handbook of Medical Hallucinogens (pp. X-X). New York, NY: Guilford PublicationsEditorials1. Luoma, J. B., Davis, A. K., Watts, R., & McCracken, L. M. (2020). Integrating contextual behavioral science withresearch on psychedelic assisted therapy: Introduction to the special section. Journal of Contextual Behavioral Science,15, 207-209.Journal Articles1. Carels, R.A., Domoff, S., Burmeister, J., Koball, A., Hinman, N., Davis, A.K. Hoffman, D. (2013).Examining perceived stereotype threat among overweight/obese adults using a Multi-Threat Framework. ObesityFacts, 6, 258-268. DOI: 10.1159/000352029

2. Davis, A.K. & Rosenberg, H. (2013). Acceptance of non-abstinence goals by addiction professionals in theUnited States. Psychology of Addictive Behaviors, 27, 1102-1109. DOI: 10.1037/a00305633. Hoffmann, E., Davis, A.K., Ashrafioun, L., Kraus, S., Rosenberg, H., Kryszak, E. Jesse, S. (2013). Evaluationof the criterion and predictive validity of the Alcohol Reduction Scale-Current Confidence (ARS-CC) in a naturaldrinking environment. Addictive Behaviors, 38, 1940-1943. DOI: 10.1016/j.addbeh.2012.12.0214. Rosenberg, H. & Davis, A.K. (2014) Differences in the acceptability of non-abstinence goals by type of drugamong American substance abuse clinicians. Journal of Substance Abuse Treatment, 46, 214-218. DOI:10.1016/j.jsat.2013.07.0055. Davis, A.K. & Rosenberg, H. (2014). The prevalence, intensity, and assessment of craving for MDMA/ecstasy inrecreational users. Journal of Psychoactive Drugs, 46, 154-161. DOI: 10.1080/02791072.2014.9015866. Davis, A.K., Leith, J., Osborn, L.A., Rosenberg, H., Ashrafioun, L., Hawley, A., Baik, K. (2014).Development and evaluation of the Marijuana Reduction Strategy Self-efficacy Scale. Psychology of AddictiveBehaviors, 28, 575-579. DOI:10.1037/a00366657. Davis, A.K., Osborn, L.A., Rosenberg, H., Cross, N., Lauritsen, K., Ashrafioun, L. . Leith, J. (2014).Psychometric evaluation of the Marijuana Reduction Strategy Self-Efficacy Scale with a sample of youngrecreational marijuana users. Addictive Behaviors, 39, 1750-1754. DOI: 10.1016/j.addbeh.2014.07.0058. Davis, A.K. & Rosenberg, H. (2015). Application of the Passionate Attachment model to recreational use ofMDMA/ecstasy. Journal of Psychoactive Drugs, 47, 24-29. DOI: 10.1080/02791072.2014.9731259. Osborn, L.A., Lauritsen, K., Cross, N., Davis, A.K., Rosenberg, H., Bonadio, F., & Lang, B. (2015). Selfmedication of somatic and psychiatric conditions using botanical marijuana. Journal of Psychoactive Drugs, 47, 345350. DOI: 10.1080/02791072.2015.109643310. Davis. A.K. & Lauritsen, K. (2016). Acceptability of non-abstinence outcome goals among students enrolled inaddiction studies programs across the United States. Substance Abuse, 37, 204-208. DOI:10.1080/08897077.2015.101570211. Bradbury, S., Davis, A.K., Leith, J., Hinman, N., Ashrafioun, L., Burmiester, J., & Dworsky, D. (2016). Attitudesand beliefs about the acceptability and justness of peer victimization of homosexual university students. Journal ofHomosexuality, 63, 808-820. DOI: 10.1080/00918369.2015.111258112. Davis, A. K. & Rosenberg, H. (2016). Using the Theory of Planned Behavior to predict implementation of harmreduction strategies by MDMA/ecstasy users. Psychology of Addictive Behaviors, 30, 500-508. DOI:10.1037/adb000016713. Davis, A.K., Bonar, E.E., Ilgen, M., Walton, M., Perron, B., & Chermack, S., (2016). Factors Associated withHaving a Medical Marijuana Card Among Veterans with Recent Substance Use in VA Outpatient Treatment.Addictive Behaviors, 63, 132-136. DOI:10.1016/j.addbeh.2016.07.00614. Ashrafioun, L., Bonadio, F. A., Baik, K.D., Bradbury, S. L., Carhart, V. L., Cross, N. A., Davis, A. K., , &Zaturenskaya, M. (2016). Patterns of use, acute subjective effects, and motivations for using synthetic cathinones(“bath salts”) in recreational users. Journal of Psychoactive Drugs, 48, 336-343. DOI: 0.1080/02791072.2016.122987515. Davis, A. K. (2017). The Dualistic Model of Passion applied to recreational marijuana consumption. AddictionResearch and Theory, 25, 188-194. DOI: 10.1080/16066359.2016.124272216. Lang, B., Rosenberg, H., Lauritsen, K. J., Davis, A. K., & Cross, N. (2017). Psychometric evaluation of the WorkAcceptance and Action Questionnaire-Student Form. Journal of College Student Development, 58, 1256-1260. DOI:10.1353/csd.2017.0097

17. Davis, A. K. and Rosenberg, H. (2017). Specific harm reduction strategies used by MDMA/ecstasy users in theUnited States and the United Kingdom. Drug Science, Policy, and Law, 3, 1-8. DOI: 10.1177/205032451771106918. Davis, A.K., Bonar, E.E., Goldstick J., Walton, M., Winters, J., & Chermack, S. (2017). Binge drinking and nonpartner violence is associated with recent gambling among Veterans in VA outpatient mental health treatment.Addictive Behaviors, 74, 27-32. DOI: 10.1016/j.addbeh.2017.05.02219. Davis, A.K., Rosenberg, H., & Rosansky, J. (2017). American counselors’ acceptance of non-abstinence outcomegoals for clients diagnosed with co-occurring substance use and other psychiatric disorders. Journal of SubstanceAbuse Treatment, 82, 29-33. DOI: 10.1016/j.jsat.2017.08.00620. Davis, A.K., Barsuglia, J., Windam-Herman, M., Lynch, M. & Polanco, M. (2017). Effectiveness of Ibogaineassisted treatment for problematic opioid consumption: Short- and long-term outcomes and current psychologicalfunctioning. Journal of Psychedelic Studies, 1, 65-73. DOI: 10.1556/2054.01.2017.00921. Davis, A.K., Lin, A., Ilgen, M. A., & Bohnert, K. (2018). Recent Cannabis Use among Veterans in the UnitedStates: Results from a National Sample. Addictive Behaviors, 76, 223-228. DOI: 10.1016/j.addbeh.2017.08.01022. Davis, A.K., Walton, M., Bohnert, K. M., Bourque, C., & Ilgen, M. (2018). Factors associated with alcoholconsumption among medical cannabis patients with chronic pain. Addictive Behaviors, 77, 166-171. DOI:10.1016/j.addbeh.2017.10.00723. Davis, A.K., Arterberry, B., Bonar, E.E., Bohnert, K.M., & Walton, M.A. (2018). Why do young people consumemarijuana? Extending motivational theory via the dualistic model of passion. Translational Issues in PsychologicalScience, 4, 54-64. DOI: 10.1037/adb000035424. Bonar, E. E., Arterberry, B. J., Davis, A. K., Cunningham, R. C., Blow, F. C., Collins, L., & Walton, M. A. (2018).Prevalence and Motives for Drugged Driving among Emerging Adults Presenting to an Emergency Department.Addictive Behaviors, 78, 80-84. DOI: 10.1016/j.addbeh.2017.11.00225. Davis, A. K., Nickelsen, T., Zucker, R. A., Bonar, E. E., & Walton, M. A. (2018). Acceptability of non-abstinenttreatment outcome goals among addiction treatment providers in Ukraine. Psychology of Addictive Behaviors, 32, 485495. DOI: 10.1037/adb000035426. Davis, A.K., Barsuglia, J. P., Lancelotta, R., Grant, R., & Renn, E. (2018). 5-Methoxy-Dimethyltryptamine:Benefits, consequences, patterns of use, motives for consumption, and acute subjective effects. Journal ofPsychopharmacology, 32, 779-792. DOI: 10.1177/026988111876906327. Davis, A. K., Arterberry, B. J., Bonar, E. E., Chermack, S. T., Cunningham, R. M., Blow, F., & Walton, M. A.(2018). Predictors of positive treatment response among youth receiving a brief alcohol intervention in theemergency department. Drug and Alcohol Dependence, 188, 102-108. DOI: 10.1016/j.drugalcdep.2018.03.04428. Davis, A.K., Renn, E., Windham-Herman, M., Polanco, M. & Barsuglia, J. (2018). A mixed method analysis ofpersisting effects associated with positive outcomes following Ibogaine detoxification. Journal of Psychoactive Drugs,online ahead of print, 1-11. DOI: 10.1080/02791072.2018.148760729. Goldstick, J., Bohnert, K., Davis, A.K., Bonar, E. E., Carter, P., Walton, M.A., & Cunningham, R. (2018). Dualtrajectories of depression/anxiety symptoms and alcohol use, and their implications for violence outcomes amongdrug-using urban youth. Alcohol and Alcoholism, 53, 659-666. DOI: 10.1093/alcalc/agy03630. Morris, D. H., Davis, A. K., Lauritsen, K. J., Rieth, C. M., Winters, J. M., & Chermack, S. T. (2018). Substanceuse consequences, mental health problems, and readiness to change among Veterans seeking substance usetreatment. Journal of Substance Abuse Treatment, 94, 113-121. DOI: 10.1016/j.jsat.2018.08.005

31. Barsuglia, J., Davis, A. K., Palmer, R., Lancelotta, R., Windham-Herman, A-M., Peterson, K., Polanco, M., Grant,R., & Griffiths, R. R. (2018). Intensity of mystical experiences occasioned by 5-MeO-DMT and comparison witha prior psilocybin study. Frontiers in Psychology, 9, 1-6. DOI: 10.3389/fpsyg.2018.0245932. Sexton, M. B., Davis, A. K., Buchholz, K., Winters, J., Rauch, S., Yzquibell, M., Bonar, E. E., Friday, S., &Chermack, S. T. (2019). Veterans with recent substance use and aggression: PTSD, substance use, and socialnetwork behaviors. Psychological Trauma: Theory, Research, Practice, and Policy,11, 424-433. DOI: 10.1037/tra000036733. Davis, A. K., So, S., Lancelotta, R., Barsuglia, J. P., & Griffiths, R. R. (2019). 5-Methoxy-N,NDimethyltryptamine (5-MeO-DMT) used in a naturalistic setting is associated with unintended improvements indepression and anxiety. The American Journal of Drug and Alcohol Abuse. DOI: 10.1080/00952990.2018.1545024.34. Bonar, E. E., Goldstick, J., Cunningham, R. C., Fernandez, A., Davis, A. K., Ilgen, M., & Walton, M. A. (2019).Individual and social factors related to trajectories of blackouts among underage drinkers in the emergencydepartment. Alcohol and Alcoholism, 54, 370-377. DOI: 10.1093/alcalc/agy08735. Griffiths, R. R., Hurwitz, E., Davis, A. K., Johnson, M. W., & Jesse, R. (2019). Survey of subjective “Godencounter experiences”: Comparisons among naturally occurring experiences and those occasioned by the classicpsychedelics psilocybin, LSD, ayahuasca, or DMT. PLOS One, 14, e0214377. DOI: 10.1371/journal.pone.021437736. Arterberry, B. J., Davis, A. K., Bonar, E. E., Walton, M. A., & Blow, F. C (2019). Predictors of empiricallyderived substance use patterns of sexual minority groups presenting to an urban emergency department. AddictiveBehaviors, 96, 76-81. DOI: 10.1016/j.addbeh.2019.04.02137. Garcia-Romeu, A., Davis, A. K., Erowid, F., Erowid, E., Griffiths, R. R., & Johnson, M. W. (2019). Cessationand reduction in alcohol consumption and misuse after psychedelic use. Journal of Psychopharmacology, 33, 10881101. DOI: 10.1177/026988111984579338. Davis, A. K. & Arterberry, B. J. (2019). Passion for marijuana use mediates the relations between refusal selfefficacy and use/consequences. Journal of Psychoactive Drugs, 51, 343-350. DOI: 10.1080/02791072.2019.159633439. Sepeda, N. D., Clifton, J. M., Doyle, L. Y., Lancelotta, R., Griffiths, R. R., & Davis, A. K. (2019). Inhaled 5methoxy-N,N-dimethyltryptamine (5-MeO-DMT): Supportive context associated with increased positive acuteand enduring effects. Journal of Psychedelic Studies. DOI: 10.1556/2054.2019.03340. Uthaug, M. V., Lancelotta, R., Szabo, A., Davis, A. K., Riba, J., & Ramaekers, J G. (2019). Prospectiveexamination of synthetic 5-methoxy-N,N-dimethyltryptamine inhalation: effects on salivary IL-6, cortisol levels,affect, and non-judgement. Psychopharmacology. E-pub ahead of print. DOI: 10.1007/s00213-019-05414-w41. Davis, A.K., Barrett, F., & Griffiths, R.R. (2020). Psychological flexibility mediates the relations between acutepsychedelic effects and subjective decreases in depression and anxiety. Journal of Contextual Behavioral Science, 15, 3945. DOI: 10.1016/j.jcbs.2019.11.00442. Garcia-Romeu, A., Davis, A. K., Erowid, F., Erowid, E., Griffiths, R. R., & Johnson, M. W. (2020). Persistingreductions in cannabis, opioid, and stimulant misuse after naturalistic psychedelic use: An online survey. Frontiersin Psychiatry – Psychopharmacology, 10, 1-16. DOI: 10.3389/fpsyt.2019.0095543. Davis, A. K., Arterberry, B. J., Schneeberger, D., Bonar, E. E., Young, S., Bauermeister, J., Cunningham, R. M.,& Walton, M. A. (2020). Evaluation of the dualistic model of passion for alcohol consumption among emergingadults engaged in risky drinking. Addiction Research and Theory, 28, 21-28. DOI: 10.1080/16066359.2019.157119244. Aday, J. S., Mitzkovitz, C. M., Bloesch, E. K., Davoli, C. C., & Davis, A. K. (2020). Long-term effect ofpsychedelic drugs: A systematic review. Neuroscience & Biobehavioral Reviews, 113, 3.017

45. Lancelotta, R. & Davis, A.K. (2020). Use of benefit enhancement strategies among 5-Methoxy-N,Ndimethyltryptamine (5-MeO-DMT) users: Associations with mystical, challenging, and enduring effects. Journal ofPsychoactive Drugs, 52, 273-281.46. Rosenberg, H., Grant, J., & Davis, A.K. (2020). Acceptance of non-abstinence as an outcome goal for individualsdiagnosed with substance use disorders: A narrative review of published research. Journal of Studies on Alcohol andDrugs, 81, 405-415.47. Davis, A. K., Averill, L. A., Basruglia, J. P., Sepeda, N. D., Amoroso, T. (2020). The effectiveness of ibogaine and5-MeO-DMT treatment for trauma-related psychological and cognitive impairment among United States SpecialOperations Forces Veterans. Chronic Stress, 4, 1-11.48. Uthaug, M. V., Lancelotta, R., Ortiz Bernal, A. M., Davis, A. K., & Ramaekers, J. G. (2020). A comparison ofreactivation experiences following vaporization and intramuscular injection (IM) of synthetic 5-methoxy-N,Ndimethyltryptamine (5-MeO-DMT) in a naturalistic setting. Journal of Psychedelic Studies, 2, 104-113.49. Davis, A. K., Clifton, J. M., Weaver, E. G., Hurwitz, E. H., Johnson, M. W., & Griffiths, R. R. (2020). Survey ofentity encounter experiences occasioned by inhaled N,N-dimethyltryptamine (DMT): Phenomenology,interpretation, and enduring effects. Journal of Psychopharmacology, 34, 1008-1020.50. Luoma, J. B., Chwyl, C., Bathje, G. J., Davis, A. K., & Lancelotta, R. (2020). A meta-analysis of placebocontrolled trials of psychedelic-assisted therapy. Journal of Psychoactive Drugs, 52, 289-299.51. Dolan, S., Arterberry, B. J., & Davis, A. K. (In Press). A quadripartite model of passion for marijuana use:Associations with consumption, consequences, craving, and satisfaction with life. Addiction Research & Theory.52. Davis, A. K., Barrett, F. S., May, D. G., Sepeda, N., Cosimano, M. P., Finan, P., Johnson M. W., Griffiths, R. R.(2020). Effects of psilocybin-assisted therapy for major depressive disorder: A randomized clinical trial. Journal ofthe American Medical Association - Psychiatry.53. Davis, A. K. Barrett, F. S., So, S., Gukasyan, N., Swift, T. C., & Griffiths, R. R. (In Press). Development of thePsychological Insight Questionnaire among a sample of people who have consumed psilocybin or LSD. Journal ofPsychopharmacology.Manuscripts Under Review1. Williams, M. T., Davis, A. K., Xin, Y., Sepeda, N. S., Grigas, P. C., Sinnot, S., & Haeny, A. M. (Revise andResubmit). Psychedelic-occasioned reductions in racial trauma symptoms, depression, anxiety, and stress amongpeople of color. Drugs: Education, Prevention & Policy.2. Barrett, F. S., Sepeda, N. D., Davis, A. K., Doss, M. K., Finan, P. H., Pekar, J. J. & Griffiths, R. R. (UnderReview). Effects of psilocybin therapy on amygdala reactivity in patients with major depressive disorder. Journal ofthe American Medical Association - Psychiatry.3. Davis, A. K. & Xin, Y. (Under Review). The acceptability of non-abstinent treatment interventions amongclinical social workers in the Unites States. Substance Use & Misuse.4. Uthaug, M. V., Davis, A. K., Haas, T. F., Davis, D. D., Dolan, S. B., Lancelotta, R., Timmermann, C., andRamaekers, J. G. (Under Review). The epidemiology of mescaline use: Patterns of use, motivations forconsumption, and perceived consequences, benefits, and acute and enduring subjective effects. Journal ofPsychopharmacology.5. Philaw-Kotov, M. L., Walton M. A., Brenneman, B., Gleckman-Krut, M., Davis, A. K., Bonar, E. E. (UnderReview). What undergraduates want in campus sexual assault prevention programming: Findings from aformative research study. Journal of American College Health.

6. Clark, D. A., Arterberry, B. J., Walton, M. A., Cunningham, R. M., Goldstic